Skip to content

Safety and efficacy of supraglottic jet ventilation for painless bronchoscopy

Safety and efficacy of supraglottic jet ventilation for painless bronchoscopy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019937
Enrollment
Unknown
Registered
2018-12-09
Start date
2021-08-23
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoscopy surgery

Interventions

Group NC:oxygen inhalation through nasal catheter
Group NPA:oxygen inhalation through the nasopharyngeal airway
Group SJOV:supraglottic jet oxygenation and ventilation through a nasopharyngeal airway

Sponsors

Shanghai Pulmonary Hospital, School of Medicine, Tongji University,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Those patients who meet the requirements for fiberoptic bronchoscopy or surgical indications proposing to undergo painless bronchoscopy; (2) Aged >= 18 years; (3) ASA grade I~III; (4) Have completed relevant ancillary tests, such as routine blood, pulmonary function, liver and kidney function, and blood clotting function; (5) Those who have signed the informed consent form with the approval of the hospital ethics committee.

Exclusion criteria

Exclusion criteria: (1) Heart failure NYHA class 3~4; (2) Severe obstructive sleep apnea syndrome (OSAHS), chronic obstructive pulmonary disease COPD GOLD class III-IV, pulmonary fibrosis, evidence of pulmonary alveoli, emphysema, pneumothorax, uncontrolled asthma; (3) End-stage liver disease, end-stage renal disease (GFR <15 ml/min); (4) Decreased basal oxygen saturation (resting SpO2 < 90%), SpO2 <95% via NC oxygen (4L/min); (5) Sinus bradycardia (basal HR < 60 beats/min) with significant symptoms associated with bradycardia; (6) Pregnant, lactating women; (7) History of allergy to narcotic drugs, history of drug abuse; (8) History of coagulation disorders, tendency to rhinorrhea, habitual epistaxis, or nasal surgery; (9) A definite acute infection of the mouth, nose and throat; (10) Pacemakers or implantable cardioverter-defibrillators; (11) Emergency surgery; (12) Patients who are participating in other clinical trials; (13) For other reasons, the researchers believe that they are not suitable for the clinical trial.

Design outcomes

Primary

MeasureTime frame
Number of cases in which SpO2<90%;

Secondary

MeasureTime frame
HR during operation;NIBP during operation;ETCO2;Hypoxemia intervention measures and intervention times;Desaturation and incidence of severe hypoxemia;

Countries

China

Contacts

Public ContactXin Lyu

Shanghai Pulmonary Hospital, School of Medicine, Tongji University,

xinlvg@126.com+86 13661869972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026